|
|
Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial
Vincent Ribrag
,
Serge Koscielny
,
Jacques Bosq
,
Thibaut Leguay
,
Olivier Casasnovas
,
et al.
Journal articles
inserm-01419476v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Cell-of-Origin (COO) Classification, BCL2 and MYC Expression Associated Outcome in Younger Patients Treated By RCHOP Front-Line Therapy Versus Intensive Regimen Followed By Autologous Transplant for De Novo Advanced Diffuse Large B Cell Lymphoma (DLBCL) : Results of the French Prospective Multicenter Randomized Trial Goelams-075
Gaëlle Laboure
,
Marie-Cecile Parrens
,
Anjarasoa Tsaranazy
,
Magali Bordier
,
Steven Le Gouill
,
et al.
55th Annual Meeting and Exposition of the American-Society-of-Hematology, Dec 2013, La Nouvelle Orléans, United States. 126 (23), pp.3920, 2015
Conference poster
hal-01290432v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.
Gandhi Damaj
,
Rémy Gressin
,
Krimo Bouabdallah
,
Guillaume Cartron
,
Bachra Choufi
,
et al.
Journal articles
inserm-00868869v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma.
Emmanuel Bachy
,
Roch Houot
,
Franck Morschhauser
,
Anne Sonet
,
Pauline Brice
,
et al.
Journal articles
hal-00933219v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|